These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 7504909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 3. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA.
    Antimicrob Agents Chemother; 1994 Feb 15; 38(2):275-81. PubMed ID: 7514855
    [Abstract] [Full Text] [Related]

  • 4. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
    Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW.
    Antimicrob Agents Chemother; 1993 Apr 15; 37(4):875-81. PubMed ID: 7684216
    [Abstract] [Full Text] [Related]

  • 5. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
    Gu Z, Fletcher RS, Arts EJ, Wainberg MA, Parniak MA.
    J Biol Chem; 1994 Nov 11; 269(45):28118-22. PubMed ID: 7525567
    [Abstract] [Full Text] [Related]

  • 6. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B.
    EMBO J; 1996 Aug 01; 15(15):4040-9. PubMed ID: 8670908
    [Abstract] [Full Text] [Related]

  • 7. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA.
    Antimicrob Agents Chemother; 1993 Jun 01; 37(6):1390-2. PubMed ID: 8392313
    [Abstract] [Full Text] [Related]

  • 8. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
    Smith RA, Remington KM, Lloyd RM, Schinazi RF, North TW.
    J Virol; 1997 Mar 01; 71(3):2357-62. PubMed ID: 9032372
    [Abstract] [Full Text] [Related]

  • 9. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA, Kemp SD, Harrigan PR.
    Science; 1995 Aug 04; 269(5224):696-9. PubMed ID: 7542804
    [Abstract] [Full Text] [Related]

  • 10. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR.
    Science; 1996 Mar 01; 271(5253):1282-5. PubMed ID: 8638110
    [Abstract] [Full Text] [Related]

  • 11. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
    Balzarini J, Pelemans H, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, De Clercq E, Karlsson A.
    Mol Pharmacol; 1996 May 01; 49(5):882-90. PubMed ID: 8622638
    [Abstract] [Full Text] [Related]

  • 12. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J.
    AIDS; 1995 Apr 01; 9(4):351-7. PubMed ID: 7540846
    [Abstract] [Full Text] [Related]

  • 13. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA.
    Antimicrob Agents Chemother; 1993 Jan 01; 37(1):130-3. PubMed ID: 8381634
    [Abstract] [Full Text] [Related]

  • 14. Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Cherry E, Slater M, Salomon H, Rud E, Wainberg MA.
    Antimicrob Agents Chemother; 1997 Dec 01; 41(12):2763-5. PubMed ID: 9420055
    [Abstract] [Full Text] [Related]

  • 15. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK, Zhu YQ, Remington KM, Phillips TR, North TW.
    Antimicrob Agents Chemother; 1996 Apr 01; 40(4):953-7. PubMed ID: 8849258
    [Abstract] [Full Text] [Related]

  • 16. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 01; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.